Welcome and Introduction
Henry R. Black, MD (Program Chairman)

The Evolving and Evidence-Based Role for Beta- Blockers Across the Clinical Risk Spectrum for Heart Disease and Hypertension—Deal or No Deal? A Year 2009 Update
Henry R. Black, MD

Defining the Current Role of Vasodilatory, Cardioselective Beta -1-Blockers for Hypertension-Mechanisms, Comparisons, and Implications for the Front Lines of Cardiovascular Specialty Practice
Michael A. Weber, MD

Beta-Blockers in the Setting of Heart Failure and Other Compelling Indications: When? How? What? In Whom?
Barry H. Greenberg, MD

A "Deal or No Deal" Summary Analysis: The Current State of Beta-Blocker Use Across the Risk Spectrum of Heart Disease
Henry R. Black, MD

Panel Discussion Question and Answer Session
Faculty Panel